<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: The <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (<z:chebi fb="61" ids="27565">PAS</z:chebi>) is an independent risk factor for <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>AIM </plain></SENT>
<SENT sid="2" pm="."><plain>To evaluate the risk of recurrence, to compare different treatments and determine the risk factors associated with recurrence and hemorrhagic complications in patients with <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and <z:chebi fb="61" ids="27565">PAS</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: Prospectively collected data from 92 patients under 45 years (71% female, mean age 33.8 Â± 8.9 years) with confirmed diagnoses of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> and <z:chebi fb="61" ids="27565">PAS</z:chebi>, treated with <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (n = 54) or aspirin (n = 38) were retrospectively analyzed </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical follow-up was obtained by neurological examination every 6 to 12 months </plain></SENT>
<SENT sid="5" pm="."><plain>Outcome measures were: recurrence of CI, symptomatic <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo>, and minor <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: During a median follow-up of 54 months (range: 12-240 months), there were 8 (9%) recurrent <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarctions</z:e>, with no difference between treatment with aspirin (n = 0) or <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (n = 8) </plain></SENT>
<SENT sid="7" pm="."><plain>The annual rate of recurrence was 0,014 person-years of follow-up </plain></SENT>
<SENT sid="8" pm="."><plain>The history of previous <z:mp ids='MP_0005048'>thrombosis</z:mp> and <z:hpo ids='HP_0005268'>spontaneous abortions</z:hpo> were more frequent in patients with recurrence </plain></SENT>
<SENT sid="9" pm="."><plain>Aspirin-treated patients more frequently came from rural areas </plain></SENT>
<SENT sid="10" pm="."><plain>Four anticoagulated patients developed <z:mp ids='MP_0001914'>bleeding</z:mp> complications, two minor <z:mp ids='MP_0001914'>bleeding</z:mp> and two <z:hpo ids='HP_0100309'>subdural hematomas</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>76% of the cases evolved with good outcome (modified Rankin scale: 0-2) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: With the limitations of a nonrandomized study, our data suggest that the risk of recurrent arterial <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> in young patients with <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> secondary to <z:chebi fb="61" ids="27565">PAS</z:chebi> is low, probably non-uniform and independent of the type of antithrombotic </plain></SENT>
</text></document>